Dr. Jack West, Swedish Cancer Institute, reviews trial evidence for the efficacy of rociletinib and osimertinib for EGFR acquired resistance not driven by a T790M mutation.
Want to check another podcast?
Enter the RSS feed of a podcast, and see all of their public statistics.
